Lv15
76 积分 2021-08-09 加入
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
3天前
已完结
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
3天前
已完结
Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis
2个月前
已完结
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
3个月前
已完结
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
5个月前
已完结
IL-1 Signal Inhibition in Alcohol-Related Hepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial of Canakinumab
10个月前
已完结
FRI0394 Efficacy and safety of canakinumab in gouty arthritis patients with chronic kidney disease stage ≥3:
10个月前
已完结
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions
10个月前
已关闭
Recent advances and evolving concepts in Still’s disease
11个月前
已完结
Biologics first: evidence reshaping Still's disease treatment
11个月前
已完结
皖公网安备34019202002308
